Quoin Pharmaceuticals Ltd DRC

Company Profile

Quoin Pharmaceuticals Ltd DRC had its IPO on 2016-07-29 under the ticker symbol QNRX.

The company operates in the Healthcare sector and Biotechnology industry. Quoin Pharmaceuticals Ltd DRC has a staff strength of 4 employees.

Stock update

Shares of Quoin Pharmaceuticals Ltd DRC opened at $5.69 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.4 - $5.72, and closed at $5.51.

This is a -1.25% slip from the previous day's closing price.

A total volume of 4,605 shares were traded at the close of the day’s session.

In the last one week, shares of Quoin Pharmaceuticals Ltd DRC have slipped by -5.42%.

Quoin Pharmaceuticals Ltd DRC's Key Ratios

Quoin Pharmaceuticals Ltd DRC has a market cap of $5.67 million, indicating a price to book ratio of 0.8247 and a price to sales ratio of 0.

In the last 12-months Quoin Pharmaceuticals Ltd DRC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-9345068. The EBITDA ratio measures Quoin Pharmaceuticals Ltd DRC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Quoin Pharmaceuticals Ltd DRC’s operating margin was 0% while its return on assets stood at -56.16% with a return of equity of -329.98%.

In Q2, Quoin Pharmaceuticals Ltd DRC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Quoin Pharmaceuticals Ltd DRC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0.0077

PEG

Its diluted EPS in the last 12-months stands at $744.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Quoin Pharmaceuticals Ltd DRC’s profitability.

Quoin Pharmaceuticals Ltd DRC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.4746. Its price to sales ratio in the trailing 12-months stood at 0.

Quoin Pharmaceuticals Ltd DRC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$16.71 million

Total Liabilities

$4.41 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Quoin Pharmaceuticals Ltd DRC ended 2024 with $16.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $16.71 million while shareholder equity stood at $9.07 million.

Quoin Pharmaceuticals Ltd DRC ended 2024 with $0 in deferred long-term liabilities, $4.41 million in other current liabilities, -2932000.00 in common stock, $-42226763.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.76 million and cash and short-term investments were $15.44 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Quoin Pharmaceuticals Ltd DRC’s total current assets stands at $15.67 million while long-term investments were $0 and short-term investments were $10.68 million. Its net receivables were $0 compared to accounts payable of $707935.00 and inventory worth $0.

In 2024, Quoin Pharmaceuticals Ltd DRC's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Quoin Pharmaceuticals Ltd DRC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$5.51

52-Week High

$50.4

52-Week Low

$5.04

Analyst Target Price

$132

Quoin Pharmaceuticals Ltd DRC stock is currently trading at $5.51 per share. It touched a 52-week high of $50.4 and a 52-week low of $50.4. Analysts tracking the stock have a 12-month average target price of $132.

Its 50-day moving average was $6.21 and 200-day moving average was $10.11 The short ratio stood at 0.03 indicating a short percent outstanding of 0%.

Around 829.5% of the company’s stock are held by insiders while 200.1% are held by institutions.